Valuation: Nektar Therapeutics

Market Cap 2.41B 2.12B 1.97B 1.81B 3.4B 230B 3.45B 23.37B 9.15B 114B 9.05B 8.85B 395B P/E 2026 *
-7.92x
P/E 2027 * -6.58x
Enterprise Value 2.41B 2.12B 1.97B 1.81B 3.4B 230B 3.45B 23.37B 9.15B 114B 9.05B 8.85B 395B EV / Sales 2026 *
58.2x
EV / Sales 2027 * 65.2x
Free-Float
99.55%
Yield 2026 *
-
Yield 2027 * -
1 day-1.92%
1 week+2.20%
Current month+0.53%
1 month+7.33%
3 months-16.26%
6 months+95.43%
Current year+65.99%
1 week 67.71
Extreme 67.71
73.98
1 month 62.58
Extreme 62.5801
77.23
Current year 33.4
Extreme 33.4
109
1 year 21.02
Extreme 21.02
109
3 years 6.19
Extreme 6.189
109
5 years 6.19
Extreme 6.189
290.55
10 years 6.19
Extreme 6.189
1,670.4
Manager TitleAgeSince
Chief Executive Officer 73 01/01/2007
Director of Finance/CFO 60 15/05/2026
Chief Tech/Sci/R&D Officer 52 01/07/2015
Director TitleAgeSince
Director/Board Member 72 01/08/2000
Chairman 69 01/05/1992
Director/Board Member 73 01/02/2007
Date Insider Type Main position Quantity % Market Cap.
7/24/26 A Free

Chief Executive Officer

57,200 0.1693%
7/24/26 A Free

Chief Technology Officer

16,500 0.0488%
6/30/26 A Sell

Chief Technology Officer

-5,681 0.0168%
Change 5-day change 1-year change 3-year change Capi.($)
-1.89%+2.20%+196.74%+758.47% 2.41B
-2.25%+1.55%+50.84%+70.04% 56.19B
-1.32%-0.97%+38.41%+77.52% 54.83B
+0.83%-0.31%-18.40%-14.32% 23.04B
-0.46%-3.89%+2.60%+388.99% 22.7B
-0.21%+0.84%+22.48%-7.92% 20.23B
0.00%+3.00%+27.41%-29.52% 17.83B
-0.97%+0.89%+37.28%+539.62% 15.65B
-6.69%-5.11%+166.00%+304.89% 15.24B
-0.04%-0.40%+25.92%+181.59% 14.03B
Average -1.32%+0.98%+54.93%+226.94% 24.21B
Weighted average by Cap. -1.32%+0.51%+39.20%+138.21%

Financials

2026 *2027 *
Net sales 41.44M 36.37M 33.87M 31.15M 58.4M 3.96B 59.4M 402M 157M 1.96B 156M 152M 6.78B 36.99M 32.46M 30.23M 27.8M 52.12M 3.53B 53.01M 359M 140M 1.75B 139M 136M 6.05B
Net income -249M -219M -204M -187M -351M -23.8B -357M -2.42B -946M -11.8B -935M -915M -40.79B -351M -308M -287M -264M -494M -33.51B -503M -3.4B -1.33B -16.62B -1.32B -1.29B -57.42B
Net Debt - -
Logo Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Employees
63
Date Price Change Volume
28/07/26 $70.01 -1.88% 374,783
27/07/26 $71.35 +0.88% 818,038
24/07/26 $70.73 +1.97% 836,066
23/07/26 $69.36 +0.06% 631,124
22/07/26 $69.32 +0.95% 508,631
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
71.35USD
Average target price
153.22USD
Spread / Average Target
+114.75%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NKTR Stock